EU approves Agios’ Pyrukynd as first oral treatment for adult thalassemia
Agios Pharmaceuticals (NASDAQ:AGIO) announced that the European Commission has granted marketing authorization for Pyrukynd (mitapivat) to treat anemia in adult patients with alpha- or beta-thalassemia.










